Orchid Pharma Limited (IN:ORCHPHARMA)
:ORCHPHARMA
Want to see IN:ORCHPHARMA full AI Analyst Report?
ORCHPHARMA Stock Chart & Stats
₹794.90
-₹2.05(-0.11%)
At close: 4:00 PM EST
₹794.90
-₹2.05(-0.11%)
Day’s Range― - ―
52-Week Range₹471.30 - ₹898.45
Previous CloseN/A
Volume34.10K
Average Volume (3M)10.21K
Market Cap
₹36.37B
Enterprise Value₹38.68B
Total Cash (Recent Filing)₹1.50B
Total Debt (Recent Filing)₹2.82B
Price to Earnings (P/E)―
Beta1.23
Next Earnings
May 25, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)10.31
Shares Outstanding50,719,105
10 Day Avg. Volume2,303
30 Day Avg. Volume10,213
Financial Highlights & Ratios
PEG Ratio12.87
Price to Book (P/B)3.13
Price to Sales (P/S)4.31
P/FCF Ratio-30.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)18
Revenue Forecast (FY)₹15.13B
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet / Low LeverageA high equity ratio and very low debt-to-equity provide lasting financial resilience. This structure reduces refinancing and interest-rate risk, preserves strategic optionality for capex or regulatory spending, and supports operations across market cycles without reliance on external debt.
Improved Profitability And Healthy MarginsReturn to profitability with sustained gross and net margins indicates durable pricing power and cost management in generics and formulations. Healthy margins create a buffer for regulatory and R&D costs, supporting reinvestment and margin resilience over the medium term.
Integrated Manufacturing And R&D CapabilitiesVertical presence across APIs, finished dosages, and in-house R&D supports faster product development, regulatory filings, and reduced supplier dependence. This integration strengthens competitive positioning in generics and export markets and supports sustainable product pipeline development.
Bears Say
Negative Free Cash Flow And Declining FCFNegative and declining free cash flow constrains the firm's ability to fund capex, working capital, and regulatory filings internally. Over months this may force external financing, delay product launches, or limit capacity expansion, reducing strategic flexibility.
Poor Cash Conversion Of EarningsLow conversion of accounting profits into cash indicates working capital or collection issues and reduces usable cash for investments. Persistent weak cash conversion increases funding risk and makes earnings less reliable as a measure of underlying cash-generating strength.
Moderate Return On EquityROE under 8% signals modest returns on shareholders' capital despite low leverage and healthy margins. This suggests limited capital efficiency or slow payoff from investments, potentially constraining long-term shareholder value creation if not improved.
Orchid Pharma Limited News
ORCHPHARMA FAQ
What was Orchid Pharma Limited’s price range in the past 12 months?
Orchid Pharma Limited lowest stock price was ₹471.30 and its highest was ₹898.45 in the past 12 months.
What is Orchid Pharma Limited’s market cap?
Orchid Pharma Limited’s market cap is ₹36.37B.
When is Orchid Pharma Limited’s upcoming earnings report date?
Orchid Pharma Limited’s upcoming earnings report date is May 25, 2026 which is in 4 days.
How were Orchid Pharma Limited’s earnings last quarter?
Orchid Pharma Limited released its earnings results on Feb 11, 2026. The company reported -₹2.487 earnings per share for the quarter, missing the consensus estimate of -₹0.3 by -₹2.187.
Is Orchid Pharma Limited overvalued?
According to Wall Street analysts Orchid Pharma Limited’s price is currently Overvalued.
Does Orchid Pharma Limited pay dividends?
Orchid Pharma Limited pays a Annually dividend of ₹3 which represents an annual dividend yield of N/A. See more information on Orchid Pharma Limited dividends here
What is Orchid Pharma Limited’s EPS estimate?
Orchid Pharma Limited’s EPS estimate is 3.
How many shares outstanding does Orchid Pharma Limited have?
Orchid Pharma Limited has 50,719,105 shares outstanding.
What happened to Orchid Pharma Limited’s price movement after its last earnings report?
Orchid Pharma Limited reported an EPS of -₹2.487 in its last earnings report, missing expectations of -₹0.3. Following the earnings report the stock price went up 0.189%.
Which hedge fund is a major shareholder of Orchid Pharma Limited?
Currently, no hedge funds are holding shares in IN:ORCHPHARMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Orchid Pharma Limited
Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical ingredients product portfolio includes oral cephalosporins, injectable cephalosporins, veterinary products, and non-antibiotics. The company's multi-therapeutic presence in anti-infectives, anti-inflammatory, central nervous system, cardiovascular segment, nutraceuticals, and other oral and sterile products, as well as offers new drug discovery systems and pharmaceutical research and development services. It also exports its products to approximately 40 countries internationally. In addition, the company provides liaising support to customers in regulatory, pharma covigilance, testing and release, retention of samples, service providers, and business development. The company was formerly known as Orchid Chemicals & Pharmaceuticals Limited and changed its name to Orchid Pharma Limited in October 2015. Orchid Pharma Limited was incorporated in 1992 and is headquartered in Chennai, India. Orchid Pharma Limited is a subsidiary of Dhanuka Laboratories Limited.
Technical Analysis
Bliss Gvs Pharma Limited
―
Gufic Biosciences Limited
―
IOL Chemicals & Pharmaceuticals Ltd.
―
Solara Active Pharma Sciences Ltd.
―
Unichem Laboratories Limited
―